|Healthcare Review: ProPhase Labs Inc, Neurocrine Biosciences, Optimer Pharmaceuticals, VIVUS, Rockwell Medical|
|By Staff and Wire Reports|
|Tuesday, 05 February 2013 15:08|
The S&P 500 has rallied 6 percent in 2013 as U.S. lawmakers reached a budget compromise and companies reported better-than- estimated earnings. The gauge is 3.4 percent below the record 1,565.15 it reached in October 2007. The Dow is 1.2 percent from its all-time high.
Following are the notable movers at mid-day on Tuesday:
ProPhase Labs Inc. (NASDAQ:PRPH) shares declined 12.35% to $1.49 in the morning hour after Matrixx Initiatives, Inc., the maker of the Zicam® cold, sinus and allergy line of products, announced today that it has withdrawn the $1.60 per share offer it made in October to acquire all of the outstanding shares of ProPhase Labs, Inc. (PRPH).
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares climbed 9.83% to $10.27. The company, on Feb. 1, announced that the Company will report its fourth quarter and year-end 2012 financial results before the Nasdaq market opens on Friday, February 8, 2013. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Friday morning, February 8, 2013 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) stock jumped 5.78% to $10.25 after the company announced that on January 31, 2013 the Inducement Award Sub-Committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 6,240 shares of common stock to 4 new employees.
VIVUS, Inc. (NASDAQ:VVUS) shares climbed 4.70% to $12.73. The company, on Jan. 7, said prescriptions for obesity drug Qsymia, its main product, rose nearly 68% in the month ended December 21 compared with the preceding four weeks, well above industry forecasts. The drugmaker said it shipped 12,978 prescriptions of Qsymia in the latest period, up from 7,749 in the four weeks ended November 23. New Qsymia prescriptions totaled 5,229 in the latest period.
Rockwell Medical Inc. (NASDAQ:RMTI) stock fell 5.06% to $6 after the company yesterday announced successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate (SFP), its investigational iron-delivery drug currently in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis patients. The PRIME study demonstrated that regular administration of SFP-iron via dialysate reduced the usage of erythropoietin stimulating agents (ESAs) during hemodialysis by 37.1% while maintaining iron balance and maximizing iron delivery.